13F Holdings
中文EN

CELC Celcuity Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1603454 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-28.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,192.9%
ROA-42.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets110.2%
Debt / equity—
Current ratio14.62x
Interest coverage-11.94x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-7.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$145.00M$104.20M$60.59M$35.29M$25.76M
SG&A expense$27.20M$9.06M$5.64M$4.10M$2.60M
Operating income-$172.19M-$113.27M-$66.23M-$39.39M-$28.36M
Interest expense$17.15M$10.28M$5.33M$2.11M$1.26M
Pretax income-$177.04M-$111.78M-$63.78M-$40.37M-$29.61M
Net income-$177.04M-$111.78M-$63.78M-$40.37M-$29.61M
EBITDA-$172.03M-$113.14M-$66.09M-$39.18M-$28.05M
EPS (basic)-3.79-2.83-2.69-2.64-2.21
EPS (diluted)-3.79-2.83-2.69-2.64-2.21
Weighted avg. shares (diluted)46.76M39.45M23.68M15.42M13.38M
Balance sheet
Cash & equivalents$165.70M$22.52M$30.66M$24.57M$84.29M
Short-term investments$275.79M$212.59M$149.92M$144.02M—
Current assets$465.66M$244.57M$190.59M$175.19M$85.35M
PP&E, net$499,000$336,000$228,782$260,294$312,444
Total assets$466.56M$245.12M$191.22M$175.70M$85.91M
Current liabilities$44.15M$31.72M$14.19M$6.88M$2.51M
Long-term debt$137.55M$105.09M$37.57M$35.76M$15.98M
Total debt$137.55M$105.09M$37.57M$35.76M$15.98M
Total liabilities$366.00M$129.50M$51.45M$41.93M$17.20M
Shareholders' equity$100.56M$115.62M$139.77M$133.77M$68.71M
Net debt-$28.16M$82.58M$6.90M$11.18M-$68.31M
Shares outstanding48.24M37.14M25.51M21.67M14.92M
Cash flow statement
Operating cash flow-$153.28M-$83.47M-$53.81M-$36.01M-$20.31M
Capital expenditure$249,000$250,000$97,644$158,768$81,898
Free cash flow-$153.53M-$83.72M-$53.91M-$36.17M-$20.39M
Investing cash flow-$64.08M-$63.07M-$5.01M-$144.03M-$81,398
Financing cash flow$360.55M$138.39M$64.91M$120.33M$93.04M
Depreciation & amortization$167,000$130,000$142,772$210,918$303,235
Stock-based compensation$21.38M$6.99M$4.90M$4.64M$2.61M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.